Furthermore, GVAX plus double checkpoint blockade (anti-CTLA-4 and anti-PD-1) enhanced tumor rejection to 100% in CT26 colon carcinoma and to 75% in ID8 ovarian carcinoma, compared to, respectively, 75 and 50% with double checkpoint blockade only (83). This evidence concerns the gene CTLA4 and colon carcinoma.